65 years of age, the prevalence is 27 % and expected to climb greatly by 2050 if current trends continue. 20 About 20 % of patients with diabetes duration less than 5 years have clinical peripheral neuropathy. 21 In type 1 patients, the prevalence of DSP is estimated to be 28 %. 22 This rate increases to at least 50 % among patients who have had diabetes for 25 years, 5, 21 resulting in DM becoming the leading cause of peripheral neuropathy. [1] [2] [3] By contrast, CIDP is relatively uncommon, although it is considered to be the most common chronic autoimmune neuropathy. 23 Previously published data on its prevalence in the general population varied greatly, with estimates ranging from one to 8.9 cases per 100,000; 9, 24, 25 however, the actual prevalence might be greatly underestimated. 17 The question of whether there is higher prevalence of CIDP in DM is controversial.
In a prospective study, Sharma et al. found a significantly higher occurrence of demyelinating neuropathy meeting the electrophysiologic criteria for CIDP in types 1 and 2 DM patients (32/189 DM patients, 16.9 %), than in nondiabetic patients (17/938 patients, 1.8 %), with a calculated odds of occurrence 11 times higher among diabetic than nondiabetic patients. The odds for DM in CIDP patients was also found to be 20 times higher than in myasthenia gravis (MG) and amyotrophic lateral sclerosis (ALS) patients. 26 Similarly, in a retrospective review of 87 CIDP patients, Rotta et al. found a high percentage of patients with DM of 26 %. 15 By contrast, in a cohort of 155 patients with CIDP, Chiò et al.
found only 14 (9.0 %) DM patients, including 12 type 2 and two type 1 patients (close to the predicted number of 13.03), concluding that there is no pathogenetic correlation between the two. 27 Similarly, although in a smaller study, Laughlin et al. found that only one of 23 CIDP patients (4 %) had DM, whereas 14 of 115 age-and sex-matched controls (12 %) had DM, concluding that DM is not a major risk factor in the development of CIDP. The perceived association of DM with CIDP was suggested to be due to a chance association or misidentification of other forms of diabetic neuropathy. 9 Any association between CIDP and DM is unclear at this time and part of this difficulty might arise from the numerous criteria available to make the diagnosis of CIDP.
Pathogenesis
Progressive loss of nerve fibers is the hallmark of DSP 4 as reflected in the electrophysiology. 28 Nonetheless, Dunnigan et al. showed that DSP can be classified into different pathophysiologic types of axonal, conduction slowing, or combined DSP with different clinical characteristics, supporting the hypothesis that pathophysiologic differences may exist within the spectrum of DSP (see Table 1 ).
Evidence of conduction slowing (likely demyelination) was found to be associated with worse glycemic control in patients with type 1 diabetes, demonstrating that metabolic factors can determine different pathophysiologic behaviors. 29 Microangiopathy is observed commonly, and is occasionally associated with potentially reversible metabolic, immunologic, or ischemic injury. 30 It has been suggested that diabetic nerve damage can expose peripheral nerve antigens to the immune system, and consequently DSP might be a predisposing event to immune-mediated neuropathies. 7 Given that recent work suggests a demyelinating component in type 1 DM patients with poor glycemic control, an adverse inflammatory process might be caused by the metabolic state. 29 In CIDP there is a progressive loss of immunologic 
Clinical Manifestations
Diabetic neuropathy has several distinct forms. The most common form is a chronic, predominantly sensory DSP, which is often painful, especially in severe forms, 33 but rarely produces major weakness on physical examination. 7 By contrast, CIDP is characterized by motor greater than sensory, proximal, and distal peripheral neuropathy, and is often painless. 9 CIDP, by definition, progresses for more than 2 months, and is associated with impaired sensation, and absent or diminished tendon reflexes. 10 The classic presentation does not address well-recognized variants, such as those with predominantly distal involvement, cranial nerve palsies, exclusively sensory polyneuropathy, markedly asymmetric disease, and even associated central nervous system (CNS) demyelination. 15 CIDP+DM patients have a longer delay from onset to diagnosis, but do not differ in the mean age of onset, gender distribution, and the type of clinical course. 15, 27 However, worse clinical manifestations can be expected in CIDP+DM patients compared with CIDP-DM patients, as they reflect the consequence of two different pathogenic processes affecting the nerves. 13 Gorson et al. found that complaints of imbalance were more frequent in CIDP+DM patients. 14 Similarly, Dunnigan et al. found that CIDP+DM subjects had more severe neuropathy based on more proximal weakness, higher Toronto Clinical Neuropathy Score (TCNS), more gait abnormality, and higher lower limb vibration potential thresholds (VPT). 13 In DSP patients with probable demyelination related to poor glycemic control compared with CIDP+DM patients (see Table 2 ), the DSP patients had less severe neuropathy, a longer duration of diabetes, and worse glycemic control suggesting differing etiologies for these entities, despite similarities in the electrophysiologic pattern of demyelination.
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Electrophysiology
The pathophysiology of DSP is mainly axonal degeneration and progressive loss of nerve fibers, resulting in reduction of the amplitudes of the sensory and motor responses. [5] [6] [7] 35 When motor conduction slowing is found, it is attributable to loss of the fastest conducting large myelinated fibers, so the conduction slowing is usually mild and seldom fulfills the electrophysiologic criteria for chronic demyelination. 39 and are the most frequently used criteria in research studies. 40 Generally speaking, the EFNS/PNS criteria include distal latency prolongation 50 % above the upper normal limit, reduction of motor conduction velocity 30 % below the lower normal limit, prolongation of F-wave latency 30 % above the upper normal limit, conduction block, temporal dispersion, and absence of F-waves in at least two motor nerves (see Table 3 ). 41 It seems that the electrophysiologic characteristics of CIDP+DM differ from those with CIDP-DM, and are generally worse, as they reflect the consequence of two different pathogenic processes affecting the nerves.
Gorson et al. reported more severe axonal loss in CIDP+DM patients on Table 4 ).
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Cerebrospinal Fluid
CSF examination in most patients with CIDP shows elevated CSF protein, usually with normal cell count. [42] [43] [44] It was suggested that elevated CSF protein in DSP patients might also be high, 45 
Sural Nerve Biopsy
The sural nerve is a sensory nerve easily accessible under local anesthesia because of its constant and superficial location. However, in a significant number of patients, sural nerve biopsy is associated with chronic pain in the distribution of the sural nerve, dysesthesia, and persistent sensory loss. 46, 47 Pathologic studies in DSP are characterized mainly by axonal degeneration and regeneration, but segmental demyelination and remyelination are also reported. 36 By contrast, the pathologic hallmark of CIDP includes segmental demyelination and remyelination, frequently resulting in onion bulb formation, together with inflammatory infiltrates. Endoneurial matrix metalloproteinase 9 (MMP-9), which is involved in the pathogenesis of inflammatory demyelinating diseases of the central and peripheral nervous systems, was suggested as an additional possible helpful biomarker in the differential diagnosis between CIDP+DM and DSP. 51 However, additional research is required to confirm this observation.
Treatment
Therapy should be initiated early in the course of CIDP to prevent continuing demyelination and secondary axonal loss leading to permanent disability. 10 The most widely used treatments for CIDP consists of intravenous immune globulins, plasma exchange, and corticosteroids, with improvement in up to 80 % of patients. 52 However, response to treatment is short lived, with most patients requiring ongoing intermittent therapy. 53 Monoclonal antibody therapies, such as rituximab and natalizumab, are promising future treatments for CIDP, but need further research to document their efficacy. 
31
Conclusion
CIDP is a treatable disease, with treatment response rates up to 80 %. 10 Although the prevalence of CIDP in DM patients was found to be high in some studies, 15, 26 others have failed to show this relationship. 9, 27 Nonetheless, treatment response rates in CIDP+DM patients are similar to rates in CIDP-DM patients, [13] [14] [15] 50 although the degree of improvement might be more limited, due to additive effects of superimposed DSP.
14 Although therapy should be initiated early in the course of the disease to prevent continuing demyelination and secondary axonal loss leading to permanent disability, 10 CIDP+DM patients are less likely to receive immune therapies, 13 possibly due to the greater challenge of diagnosing CIDP in these patients. This problematic systematic failure to identify and treat CIDP in patients with diabetes requires immediate clinical attention and further research. Any polyneuropathy in DM patients that is not distal, symmetric, or sensory predominant, or that has features compatible with demyelination on nerve conduction studies, should raise the possibility of an alternative diagnosis such as CIDP, which is highly treatable, and therefore requires further specialized neurologic investigation. n
